Navigation Links
Multiple Myeloma Therapies Market (MM) - RRMM and NDDM Drugs Analysis in New Research Report at ReportsnReports.com
Date:9/22/2013

Dallas, TX (PRWEB) September 22, 2013

The report provides an overview of the therapies for Multiple Myeloma (Newly diagnosed - NDMM and relapsed/ refractory - RRMM), unmet need, and limitations of the current standard of care (SoC) for relapsed and refractory MM pts. The report highlights the competition and commercial opportunity in pursuing this therapy area – Comprehensive list of the early and late stage drugs in the clinic, their MoA and the companies developing them.

Detailed financial and competitive analysis of the companies leading in this field for this indication – Celgene, Amgen (post-acquisition of Onyx pharma), and MorphoSys are available within this full report “Treating Refractory Hematological Malignancies – Multiple Myeloma (MM): New Treatment Options Driving In-Licensing and M&A - http://www.reportsnreports.com/reports/268467-treating-refractory-hematological-malignancies-multiple-myeloma-mm-new-treatment-options-driving-in-licensing-and-ma.html ”. Key M&A activities that have taken place in this area in the last 5 years and a list of products in early /late-stages of development available for in-licensing are highlighted in the report. This report is built using primary and secondary research data and in-house proprietary database.

Reasons to buy the report:

  •     Useful for investors, Scientists, Business development managers of Pharma companies with focus in oncology to address the following-
  •     What are the opportunities or new approaches to be deployed in the R&D of the company?
  •     List of validated and new targets
  •     In-licensing opportunities – Is the way to go forward and be in the race?
  •     Commercial opportunity and companies’ valuation.

Key points discussed in the report:

  •     Overview of the Disease and Unmet need
  •     Drugs in the pipeline: NDMM & RRMM – Mechanism of Action (MoA) and Clinical Stage of development
  •     Comparative Clinical data of Late-stage Pipeline in RRMM and NDDM
  •     Ongoing Clinical trial Details of Key Drugs in Pipeline
  •     Key milestones
  •     MPA view on the Future of the drugs in the late-stage pipeline
  •     Launch Timeline and Commercial Opportunity of Late-stage pipeline
  •     M&A and Licensing deals in the last 5 years
  •     In-licensing and/or M&A Opportunity
  •     Detailed Company analysis includes Clinical data of drugs, Milestones, and Valuation – Amgen (AMGN), Celgene (CELG), and MorphoSys (MOR)

Buy a copy of report at http://www.reportsnreports.com/purchase.aspx?name=268467.

Major Points from Table of Contents:
1.    Executive Summary
2.    Investment Drivers of The Select Companies Covered
3.    Multiple Myeloma (MM)

  •     Disease Overview
  •     Current Standard of Care
4.    Novel Targets including Monoclonal Antibodies And Small Molecules Offer In-Licensing Opportunity
  •     Overview of Targets involved
  •     Late-stage pipeline – Small Molecules
  •     Late-stage pipeline – Monoclonal Antibodies
5.    Ongoing Clinical Trial Details of Key Drugs in the Pipeline
6.    Key Milestones
7.    MPA View on the Future of the Drugs in the Late-Stage
  •     Launch Timeline and Commercial Opportunity of Late-stage
Pipeline (RRMM and NDMM)
  •     Drivers of M&A / Licensing Deals in MM
8.    Detailed Company Analysis (incl. Clinical Data of Drugs, Milestones, and Valuation)

Browse more reports on Biotechnology Market at http://www.reportsnreports.com/market-research/biotechnology/ and other reports by MP Advisors Market at http://www.reportsnreports.com/publisher/mp-advisors/.

About Us
ReportsnReports.com is an online market research reports (http://www.reportsnreports.com/) library of 200,000+ reports and in-depth studies of 5000+ micro markets. Our database includes reports by leading publishers from across the globe.

Read the full story at http://www.prweb.com/releases/multiple-myeloma-therapie/market-rrmm-and-nddm-drug/prweb11145117.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Scientists uncover multiple faces of deadly breast cancer
2. Experimental Pill for Multiple Sclerosis Shows Promise
3. Fish Oil Supplements Wont Help in Multiple Sclerosis: Study
4. Kessler Foundation scientist awarded $554,000 for multiple sclerosis employment research
5. Low-dose whole-body CT finds disease missed on standard imaging for patients with multiple myeloma
6. Multiple thought channels may help brain avoid traffic jams
7. Study shows benefit of new maintenance therapy for multiple myeloma
8. FDA Issues Multiple Sclerosis Drug Alert
9. Pot Might Help Ease Multiple Sclerosis Symptoms
10. Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant
11. Multiple sclerosis patients have lower risk of cancer: UBC-VCH research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... ... launch of its 60-day free trial program for all of the company’s desktop ... offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use an ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... two ostomy patients, standing as living proof that attitude and determination can combine ... and issues that spike around the holidays. This campaign will offer patients a ...
(Date:12/2/2016)... Hawaii (PRWEB) , ... December 02, 2016 , ... ... 2016 at the Hyatt Regency Waikiki Beach Resort and Spa in Honolulu, offering ... in the field of pain management. , The demand for supplemental training ...
(Date:12/2/2016)... ... December 02, 2016 , ... "Pro3rd Accents Volume 2 is ... create versatile lower third titles with just a few clicks of the mouse," said ... includes 30 lower third animations. Choose from various styles with accented animations, rigid boxes, ...
(Date:12/2/2016)... ... 02, 2016 , ... ‘Tis the season for giving! Today, 20 creative teams ... Family Partnership and the Drug Enforcement Administration as part of the National Red Ribbon ... winning schools who decorated their campuses with this year’s Red Ribbon Week theme: “YOLO. ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Columbia , December 2, 2016 bioLytical Laboratories, ... INSTI HIV-Selbsttest, bei den Mitgliedern des Apothekenbundes von Kenia eingeführt. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ...
(Date:12/2/2016)... BEIJING , Dec. 2, 2016 ... ("Lianluo Smart" or "the Company") which develops, markets ... products in China and ... Cardiovascular Disease Diagnosis and Treatment New Progress Forum, ... Guangdong Province , Guangdong Provincial ...
(Date:12/2/2016)... Research and Markets has announced the addition of Jain ... and Companies" to their offering. ... , , Drug ... market value of drug delivery technologies and the anticancer drugs are ... to organs involved and the types of cancer as well as ...
Breaking Medicine Technology: